Evidence map›Paper›PMID 33544754›Full record

ArticlePloS one2021

Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda.

Erisa Sabakaki Mwaka, Ian Guyton Munabi, Barbara Castelnuovo, Arvind Kaimal, William Kasozi, Andrew Kambugu, Philippa Musoke, Elly Katabira

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Erisa Sabakaki MwakaSchool of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0003-1672-9608
Ian Guyton MunabiSchool of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Barbara CastelnuovoInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Arvind KaimalInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
William KasoziInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Andrew KambuguSchool of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Philippa MusokeDepartment of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-1875-202X
Elly KatabiraDepartment of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Infectious Diseases Institute · UGMakerere University · UG

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
NIAID NIH HHS P30 AI027767
6 · The paper itself

Abstract

backgroundThis study set out to determine the prevalence of low bone mass following long-term exposure to antiretroviral therapy in Ugandan people living with HIV.

methodsA cross-sectional study was conducted among 199 people living with HIV that had been on anti-retroviral therapy for at least 10 years. All participants had dual X-ray absorptiometry to determine their bone mineral density. The data collected included antiretroviral drug history and behavioral risk data Descriptive statistics were used to summarize the data. Inferential statistics were analyzed using multilevel binomial longitudinal Markov chain Monte Carlo mixed multivariate regression modelling using the rstanarm package.

resultsOne hundred ninety nine adults were enrolled with equal representation of males and females. The mean age was 39.5 (SD 8.5) years. Mean durations on anti-retroviral treatment was 12.1 (SD 1.44) years, CD4 cell count was 563.9 cells/mm3. 178 (89.5%) had viral suppression with <50 viral copies/ml. There were 4 (2.0%) and 36 (18%) participants with low bone mass of the hip and lumbar spine respectively. Each unit increase in body mass index was associated with a significant reduction in the odds for low bone mineral density of the hip and lumbar spine. The duration on and exposure to the various antiretroviral medications had no significant effect on the participant's odds for developing low bone mass. All the coefficients of the variables in a multivariable model for either hip or lumbar spine bone mass were not significant.

conclusionThese results provide additional evidence that patients on long term ART achieve bone mass stabilization. Maintaining adequate body weight is important in maintaining good bone health in people on antiretroviral therapy.

Indexed as

AdultAnti-HIV AgentsBone DensityBone Diseases, MetabolicCohort StudiesCross-Sectional StudiesFemaleHIV InfectionsHumansMaleMiddle AgedUgandaAnti-HIV Agents

Identifiers

PMID33544754
PMCPMC7864439
OpenAlexW3126475406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.